Here are the latest growth forecasts for the CSL share price
Image source: Getty Images
It has been a difficult time for the CSL Ltd (ASX: CSL) share price, which has declined 18% in the past year as investors digest the developing healthcare situation under the Trump administration in the US.
As Australia’s largest ASX healthcare share, the business is an important piece of the S&P/ASX 200 Index (ASX: XJO); its decline has affected many Aussie investors.
But is the decline justified, or is there a rebound opportunity? Let’s examine what some experts think of the business.
Largely optimistic on the CSL share price
According to Commsec’s collation of analyst ratings, the ASX healthcare share has (at least) 13 buy ratings and one hold rating. Overall, that’s a very positive view.
UBS is one of…
